InvestorsObserver
×
News Home

How Does Alaunos Therapeutics Inc (TCRT) Stock Rank on Wall Street Monday?

Monday, December 18, 2023 01:34 PM | InvestorsObserver Analysts

Mentioned in this article

How Does Alaunos Therapeutics Inc (TCRT) Stock Rank on Wall Street Monday?

Wall Street is positive on Alaunos Therapeutics Inc (TCRT). On average, analysts give Alaunos Therapeutics Inc a Hold rating. The average price target is $0.2, which means analysts expect the stock to add by 300.00% over the next twelve months. That average ranking earns Alaunos Therapeutics Inc an Analyst Rating of 5, which is better than 5% of stocks based on data compiled by InvestorsObserver.

Overall Score - 3
Wall Street analysts are rating TCRT a Hold today. Find out what this means to you and get the rest of the rankings on TCRT!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Alaunos Therapeutics Inc Stock Today?

Alaunos Therapeutics Inc (TCRT) stock is trading at $0.05 as of 1:28 PM on Monday, Dec 18, a gain of $0.01, or 16.92% from the previous closing price of $0.05. The stock has traded between $0.05 and $0.06 so far today. Volume today is more active than usual. So far 77,272,620 shares have traded compared to average volume of 4,809,022 shares. Click Here to get the full Stock Report for Alaunos Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App